Lupin rose 2.21% to Rs 2,393.80 after it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in ...
Lupin receives tentative US FDA approval for Enzalutamide Tablets, offering new dosing options as a bioequivalent to Xtandi.
The USFDA has tentatively approved the 40 mg and 80 mg strengths as bioequivalent to Xtandi Tablets of Astellas.
Lupin said it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengths of 40 mg, 80 mg, ...
According to the company, the US FDA has found Lupin's 40 mg and 80 mg tablets to be bioequivalent to Astellas Pharma's ...
Lupin receives USFDA tentative approval for its generic enzalutamide tablets, a prostate cancer treatment. Bioequivalent to ...
Lupin secures tentative USFDA approval for generic enzalutamide tablets for castration‑resistant prostate cancer, including ...
Lupin has received tentative approval from the Food and Drug Administration for enzalutamide tablets, 40 mg, 80 mg, 120 mg and 160 mg. Xtandi is used to treat certain types of pro ...
Lupin Limited has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for enzalutamide ...
Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat ...
Montreal Gazette on MSN
Lupin receives tentative approval from US FDA for enzalutamide tablets
MUMBAI, India and NAPLES, Fla., June 26, 2026 /CNW/ — Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: ...
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results